... drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.
News
- Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of ...
- Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio ...
- Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS ...
... from the Phase 3 RECOVER clinical study was presented during the 2018 San Antonio Breast Cancer Symposium ® (SABCS). ... Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, ...
- Recon: HHS Defends Drug Pricing Proposal; Mallinckrodt to Spin Off Specialty Generics Business
Pharmaceuticals & Biotechnology ... Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium (Press); Puma Biotechnology Presents ...
- Let's make Texas the 'third coast' for biotech
Texas has made a name for itself in biotech by supporting premier ... In San Antonio, one of every six workers is employed in the city's flourishing ...